Clinical News

British Society of Gastroenterology statement on the proposed removal of prescriptions for GFD

Friday, 23 September 2016 09:36

The proposed removal by CCGs of prescriptions for Gluten Free Diets (GFD) is an important issue for the British Society of Gastroenterology (BSG) as it poses a direct impact on the care of patients with coeliac disease, as well as wider cost implications for the health economy.

The BSG's membership includes most of the consultants and specialists in gastroenterology in the UK that treat patients with coeliac disease and we would like to put on record our support for Coeliac UK on this issue. Adherence to the gluten-free diet remains the complete medical treatment and having coeliac disease therefore requires significant dietary modification. The use of gluten-free substitute staple foods facilitates the necessary dietary adaptation. Rates for adherence to the gluten-free diet can vary between 42-91% [1] and gluten-free staples on prescription have been related to adherence [2].

BSG Statement on the findings of the IBD Audit Report

Commenting, Dr Barney Hawthorne, Chairman of the IBD Section at the BSG, said:

"The British Society of Gastroenterology (BSG) welcomes the findings of the latest round of the UK IBD Audit published today by the Royal College of Physicians, particularly noting the data on the use of biosimilar versions of infliximab in the NHS, and welcomes the contribution of BSG members to the findings.

"In February this year the BSG has published a guidance document supporting their use in IBD patient care. The guidance advocates their use when prescribed by brand name, and emphasises the importance of ongoing pharmacovigilance for patients receiving these drugs through ongoing data collection through the UK IBD Registry.

"With the NHS facing significant increasing financial pressures, biosimilars contribute towards improving IBD patient care and outcome while creating efficiency savings of up to £3million annually in this therapeutic area alone. We are encouraged by the reports key findings, including biosimilar versions of infliximab being shown to be as effective as other originator versions. It is vital that the reductions in costs to the NHS are used to reinvest in improvements to IBD services.

"The BSG have worked hard with partners to develop a wider IBD programme in the UK – encompassing the IBD Audit, BSG’s IBD Registry and IBD Standards – and hope that this collaboration will continue to benefit patients with IBD."

UK National Screening Committee (UK NSC)

Friday, 02 September 2016 09:21

Stakeholder Conference 2016

Following the success of last year's inaugural event, this year's conference will be in London on Wednesday 14 December. As well as highlighting recent work of the UK NSC it will also mark the 20th anniversary since the committee was formed.

Confirmed speakers include:

  • Sir Muir Gray, the UK NSC's first Programme Director
  • Dr Angela Raffle, co-author of "Screening: Evidence and Practice"
  • Prof Bob Steele, new Chair of the UK NSC
  • Dr Anne Mackie, PHE Screening Director

IBD Registry Update: September 2016

Thursday, 01 September 2016 10:05

Local value of patient data - the Dorset experience

With the launch of the IBD Registry web tool last month, we're all set for every IBD team in the UK to join in, and to start to benefit from collecting useful local data to help deliver better patient care and support service development. Here Pearl Avery describes the approach she took to entering data on the PMS, involving patients in the process and the value of the information collected in the first ten months. This included being able to achieve CCG funding for the helpline for the first time in 20 years.

Over 160 teams have registered to be part of the project now. If you haven't registered to join yet, please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Page 8 of 14